Your browser doesn't support javascript.
loading
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard, Erwan; Tronci, Elisabetta; Pioli, Elsa Y; Li, Qin; Porras, Gregory; Björklund, Anders; Carta, Manolo.
Afiliación
  • Bezard E; Institute for Neurodegenerative Diseases, Bordeaux University, Bordeaux, France.
Mov Disord ; 28(8): 1088-96, 2013 Jul.
Article en En | MEDLINE | ID: mdl-23389842
ABSTRACT
The serotonin (5-hydroxytryptamine [5HT]) system has recently emerged as an important player in the appearance of l-3,4-dihydroxyphenylalanine (levodopa [l-dopa])-induced dyskinesia in animal models of Parkinson's disease. In fact, dopamine released as a false transmitter from serotonin neurons appears to contribute to the pulsatile stimulation of dopamine receptors, leading to the appearance of the abnormal involuntary movements. Thus, drugs able to dampen the activity of serotonin neurons hold promise for the treatment of dyskinesia. The authors investigated the ability of the mixed 5-HT 1A/1B receptor agonist eltoprazine to counteract l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned rats and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques. The data demonstrated that eltoprazine is extremely effective in suppressing dyskinesia in experimental models, although this effect was accompanied by a partial worsening of the therapeutic effect of l-dopa. Interestingly, eltoprazine was found to (synergistically) potentiate the antidyskinetic effect of amantadine. The current data indicated that eltoprazine is highly effective in counteracting dyskinesia in preclinical models. However, the partial worsening of the l-dopa effect observed after eltoprazine administration represents a concern; whether this side effect is due to a limitation of the animal models or to an intrinsic property of eltoprazine needs to be addressed in ongoing clinical trials. The data also suggest that the combination of low doses of eltoprazine with amantadine may represent a valid strategy to increase the antidyskinetic effect and reduce the eltoprazine-induced worsening of l-dopa therapeutic effects.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piperazinas / Agonistas de Receptores de Serotonina / Discinesia Inducida por Medicamentos Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2013 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piperazinas / Agonistas de Receptores de Serotonina / Discinesia Inducida por Medicamentos Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2013 Tipo del documento: Article País de afiliación: Francia